Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206065 | 0.94 | TSHR (0.46) | TSHRALDH1A1SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL25340146 | 0.87 | TSHR (0.57) | TSHRALDH1A1KDM4EPLA2G2C | |
| SCHEMBL19454696 | 0.86 | TSHR (0.43) | TSHRALDH1A1SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL3116791 | 0.81 | TSHR (0.48) | TSHRALDH1A1TAS1R3TAS1R1LMNA | |
| SCHEMBL9211399 | 0.80 | TSHR (0.53) | TSHRALDH1A1KDM4ELMNAPLA2G2C | |
| SCHEMBL3123165 | 0.80 | TSHR (0.44) | TSHRALDH1A1TAS1R3TAS1R1PLA2G2C | |
| SCHEMBL11897547 | 0.78 | SIGMAR1 (0.46) | TSHRALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL11684924 | 0.78 | TSHR (0.50) | TSHRALDH1A1MEN1KMT2APLA2G2C | |
| SCHEMBL19302134 | 0.78 | TSHR (0.39) | TSHRALDH1A1SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL14398801 | 0.77 | TSHR (0.44) | TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2023-05-25 | — | — | US | disclosed |
| US-20200352966-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158053-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | TSHR 3861/4885ALDH1A1 1078/4885SIGMAR1 4800/4885 |
| US-20200352966-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | TSHR 3861/4885ALDH1A1 1078/4885SIGMAR1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.